KLOW

KLOW Overview

The KLOW Blend combines GHK-Cu, BPC-157, TB-500, and KPV into a single formulation studied for its potential influence on molecular signaling and systemic regulation. In laboratory and preclinical models, these peptides have been investigated for their effects on matrix remodeling, angiogenesis, cytokine modulation, and extracellular matrix activity. Together, they provide a platform for exploring synergistic pathways in molecular dynamics, immune signaling, and vascular biology. Pickart L. & Margolina A. 2018

History

The KLOW Blend draws on several decades of peptide research. GHK-Cu, first identified in biological plasma samples in the 1970s, has been studied for gene expression and matrix signaling. BPC-157, synthesized in the 1990s as a gastric protein fragment analog, has been explored for angiogenic and structural processes. TB-500, derived from thymosin beta-4 research in the 1960s, has been examined for angiogenesis and molecular migration. KPV, a C-terminal fragment of α-MSH, has been evaluated for cytokine-modulating and immunomodulatory activity. Collectively, these peptides represent areas of ongoing investigation into experimental biology, vascular pathways, and immune signaling. The KLOW Blend is intended for research use only. Maquart F.X. et al. 1988

KLOW Structure

CAS #:

49557-75-7

Molecular Formula:

C₁₄H₂₄CuN₆O₄

Molecular Weight:

340.9 g/mol

PubChem ID:

5311476